With more ongoing research into biomarkers, these diagnostics tests can give clinicians better clarity on how to define Alzheimer’s Disease, as well as other disease profiles on the cognitive decline continuum. In this educational sharing session hosted by Roche and Eisai, two specialists in neurodegenerative disorders in Singapore – Associate Professors Nagaendran Kandiah and Ng Kok Pin – give a comprehensive overview of the role of biomarkers in diagnosing Alzheimer’s Disease, why it’s important to use biomarkers early in the diagnosis process, and how efforts are being undertaken to update frameworks that were written as recently as 2018.